Karen Tornøe

Karen Tornøe holds a MD and Ph.D. degree from the University of Copenhagen. In addition to a broad clinical experience as MD she has a long experience within clinical drug development and regulatory strategies. Karen Tornøe was working 4 years as Senior Medical Officer at the Danish Medicine Agency and as Danish alternate of the Paediatric Committee at EMA before she joined Novo Nordisk as International Medical Director in 2011. In this position, she has been involved in clinical trials planning, execution and reporting, product safety and successful regulatory outcomes for Victoza and Saxenda. In 2017 Karen Tornøe was appointed to Senior Director, Regulatory Affairs and in 2018 to Scientific Medical Director, Global Medical Affairs, also in Novo Nordisk.
Position CMO since 2019
Year of Birth 1967
Holding of shares in Cytovac AB
(as of Dec 31, 2018)
Other ongoing assignments Karen Tornøe does not have other ongoing assignments.
Previous Assignments (within the last 5 years) Senior International Medical Director, Senior Director and Scientific Medical Director in Medical & Science, Regulatory- and Medical Affairs, respectively at Novo Nordisk A/S.
Independent in relation to the company and its management Yes
Independent in relation to larger shareholders Yes

Error, cant find that post.